Risk stratification has become central to strategies for the prevention of coronary heart disease, with the implication that priority is given to those at highest risk (ie, those with established heart disease). However, such stratification using the conventional risk estimation models may not be accurately achieved in individuals without symptoms, especially those in younger age groups whose 10-year "short-term" estimated risk seems low.

For example, while the Framingham Risk Score is acknowledged as "a great advance" in the estimation of risk (and thus in the primary prevention of CHD), most younger individuals and virtually all women are defined as low risk, despite apparent and significant differences in their actual risk factor burden.

Now, a new study reported online by Circulation suggests that many younger individuals defined as low risk by conventional risk stratification methods may not remain at low risk throughout their lives.(1)

The study included 2988 individuals under 50 years of age from the Coronary Artery Risk Development in Young Adults (CARDIA) study and 1076 from the Multi-Ethnic Study of Atherosclerosis (MESA). Short-term (10-year) risk was assessed according to the Framingham Risk Score, but added to this risk assessment model were other factors indicative of a longer lifetime risk.(2) Combination of the two risk assessment models allowed risk stratification in three groups: low 10-year/low lifetime risk; low 10-year/high lifetime risk; and high 10-year risk or diagnosed diabetes mellitus. Baseline levels and change in levels of subclinical atherosclerosis (as represented by coronary artery calcium or carotid intima-media thickness) were then compared across the three risk groups. And results showed that those in the low 10-year/high lifetime risk group had a greater subclinical disease burden and greater incidence of atherosclerotic progression than those in the low 10-year/low lifetime risk group, even at younger ages.

"Thus, long-term risk estimates in younger patients may provide new information regarding risk prediction that is not usually available using only a 10-year risk model," said the study's first author Dr Jarrett Berry from UT Southwestern Medical Center, Dallas.

The main weakness of a conventional risk estimation model such as the Framingham Risk Score is the dominance of age, says cardiologist Professor Wolfgang König from the University of Ulm Medical Centre in Germany speaking on behalf of the European Society of Cardiology. "It means that 90 per cent of people of a relatively younger age are defined as low risk. But experience tells us that a low short-term risk in younger subjects may not reflect their true risk. We see many young patients with an apparently low short-term risk who actually have advanced heart disease. That's why young patients are still a challenge in cardiology."

Professor König adds that the study raises an attractive concept in risk stratification which may well provide a mechanistic explanation for the discrepancy between "low risk" but advanced disease in young people. In public health terms, such an approach may well allow more precise differentiation between various risk groups. "The earlier we can identify risk, the higher the chance of preventing serious disease," he says.



NOTES:

1. Berry JD, Liu K, Folsom AR, et al. Multi-Ethnic Study of AtherosclerosisDisease. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease. The Coronary Artery Risk Development in Young Adults Study and Multi-Ethnic Study of Atherosclerosis. Circulation 2009; e-pub ahead of print, DOI: 10.1161/CIRCULATIONAHA.108.800235

2. Lifetime risk was estimated according to five mutually exclusive risk factors - blood pressure, total cholesterol, diabetes, smoking and predicted risk.

Source: ESC Press Office
European Society of Cardiology

Tag Cloud

Buy Actonel Without Prescription
Buy Adefovir Without Prescription
Buy Allopurinol Without Prescription
Buy Antabuse Without Prescription
Buy Arava Without Prescription
Buy Armour Without Prescription
Buy Atarax Without Prescription
Buy Azathioprine Without Prescription
Buy Bayer ASA Aspirin Without Prescription
Buy CellCept Without Prescription
Buy Colchicine Without Prescription
Buy Cyklokapron Without Prescription
Buy Cystone Without Prescription
Buy Detrol Without Prescription
Buy Dexamethasone Without Prescription
Buy Diamox Without Prescription
Buy Diltiazem Cream Without Prescription
Buy Ditropan Without Prescription
Buy Epogen Without Prescription
Buy Fosamax Without Prescription
Buy HIV Test Without Prescription
Buy Human Growth Hormone Without Prescription
Buy Kenalog Without Prescription
Buy Meclizine Without Prescription
Buy Mestinon Without Prescription
Buy Motilium Without Prescription
Buy Naltrexone Without Prescription
Buy Nimotop Without Prescription
Buy Persantine Without Prescription
Buy Potassium Citrate Without Prescription
Buy Prednisolone Without Prescription
Buy Probenecid Without Prescription
Buy Prograf Without Prescription
Buy Pyridium Without Prescription
Buy Reglan Without Prescription
Buy Rocaltrol Without Prescription
Buy Rogaine Without Prescription
Buy Synthroid Without Prescription
Buy Triamcinolone Without Prescription
Buy Urispas Without Prescription
Buy Urivoid Without Prescription
Buy Ursodiol Without Prescription
Buy Vasodilan Without Prescription
Buy Vesicare Without Prescription
Buy Zofran Without Prescription
Buy Anti Flu Face Mask Without Prescription
Buy Anti-Bacterial Face Mask Without Prescription
Buy Atripla Without Prescription
Buy Combivir Without Prescription
Buy Didanosine Without Prescription
Buy Epivir Without Prescription
Buy Famvir Without Prescription
Buy Nevirapine Without Prescription
Buy Retrovir Without Prescription
Buy Ribavirin Without Prescription
Buy Stavudine Without Prescription
Buy Sustiva Without Prescription
Buy Truvada Without Prescription
Buy Valtrex Without Prescription
Buy Zovirax Without Prescription